公开(公告)号：WO2021067714A2

公开(公告)日：2021-04-08

申请号：PCT/US2020/053964

申请日：2020-10-02

申请人： TAKEDA VACCINES, INC.

发明人： TSUJI, Isamu ,  DEAN, Hansi ,  EGAN, Michael

IPC分类号： G01N33/50 ,  C07K14/18 ,  C07K14/005 ,  C07K16/1081 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2770/16023 ,  C12N2770/24123 ,  C12N7/00 ,  G01N33/502

摘要： The present invention relates to methods for determining affinity, binding kinetics and/or concentration of an antibody or of an antibody mixture specific for a virus using virus-like particles (VLPs) and/or live viruses or inactivated viruses attached to biosensors. Further, the present invention relates to the VLPs and live or inactivated viruses attached to biosensors and methods for producing them.

公开(公告)号：WO2021092555A2

公开(公告)日：2021-05-14

申请号：PCT/US2020/059667

申请日：2020-11-09

申请人： KIYATEC, INC.

发明人： APPLETON, Kate ,  DESROCHERS, Tessa

IPC分类号： G01N33/50 ,  G01N33/574 ,  C12M1/00 ,  C12M1/42 ,  C12N5/078 ,  C12N5/071 ,  C12M35/08 ,  C12N2503/04 ,  C12N5/0636 ,  C12N5/0693 ,  C12N5/0697 ,  G01N2800/52 ,  G01N33/5011 ,  G01N33/502 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/57484

摘要： The present application contemplates methods of screening therapeutic agents for treating cancer comprising co-culturing immune cells and tumor cells isolated from a subject under conditions that allow the immune cells and the tumor cells to form a cancer spheroid. The cancer spheroid may then be exposed to at least one therapeutic agent, and the responsiveness of the tumor cells in the spheroid to the therapeutic agent may be measured.

公开(公告)号：WO2023283599A2

公开(公告)日：2023-01-12

申请号：PCT/US2022/073510

申请日：2022-07-07

申请人： MEDIC LIFE SCIENCES INC.

发明人： HAN, Kyuho ,  LEE, Hong-Pyo

IPC分类号： A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12N15/10 ,  C12N15/11 ,  C12Q1/68 ,  C40B20/04 ,  C40B40/06 ,  C07K14/70532 ,  C07K16/2803 ,  C07K16/2809 ,  C07K19/00 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/33 ,  C07K2319/60 ,  C12N15/1037 ,  C12N15/1065 ,  C12N15/1075 ,  C12N15/111 ,  C12N2310/20 ,  C12N2330/31 ,  C40B40/02 ,  G01N2500/04 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/502

摘要： The present disclosure provides a high-throughput screening system and method for identification of novel drugs and drug targets. The method enables large-scale analysis of interactions between allogeneic pairs of target cells and immune cells by using an immune-bridge protein, library of guide RNA, and/or 3D tumor model. The immune-bridge protein comprises (a) a scFv against an immune cell marker, preferably for CD3 or NKp46 (b) a transmembrane domain, preferably from B7, (c) a cytoplasmic domain, preferably from B7 and (d) a reporter domain, preferably a fluorescent protein.

公开(公告)号：WO2020031149A2

公开(公告)日：2020-02-13

申请号：PCT/IB2019/056803

申请日：2019-08-09

申请人： NOVARTIS AG

发明人： BAI, Jirong ,  HELDWEIN, Kurt Alex ,  LINDSLEY, Loren Daniel

IPC分类号： G01N33/502

摘要： GFRAL extracellular domains comprising domains D2 and D3 are disclosed. The disclosure further relates to methods and compositions for screening and evaluating the activity of a GFRAL ligand, such as a GDF15 peptide, using the GFRAL extracellular domains provided herein. Also disclosed are methods and compositions for treating obesity, reducing appetite, and/or reducing body weight using the GFRAL extracellular domains provided herein.

公开(公告)号：WO2022256251A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031302

申请日：2022-05-27

申请人： GENENTECH, INC. ,  UNIVERSITY OF COPENHAGEN

发明人： NOLAND, Cameron, L. ,  PAYANDEH, Jian, Mehr-Dean ,  PLESS, Stephan, Alexander ,  CHUA, Han Chow ,  KSCHONSAK, Marc

IPC分类号： C07K14/705 ,  G01N33/50 ,  G01N2500/02 ,  G01N33/502 ,  G01N33/6872

摘要： The present disclosure relates to mutant human NaX ion channel ("NaX") proteins and screening methods using a mutant human NaX that may be used to identify molecules that modulate the activity of human NaX. For example, in some embodiments, screening methods involve performing an ion channel assay on a mutant human NaX in the presence of a potential NaX modulator. The disclosure also relates to molecules that act as modulators of human NaX and associated kits for detecting such molecules.

公开(公告)号：WO2017158610A1

公开(公告)日：2017-09-21

申请号：PCT/IL2017/050339

申请日：2017-03-17

申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.

发明人： MERBL, Yifat ,  WOLF-LEVY, Hila ,  LEVIN, Yishai ,  DASSA, Bareket

IPC分类号： C12Q1/37 ,  G01N33/50 ,  G01N2333/96425 ,  G01N33/502 ,  G01N33/573

摘要： A method of isolating barrel-like proteases is disclosed. The method comprising isolating barrel-like proteases from a biological sample containing the barrel-like proteases under conditions that maintain the content of the barrel-like protease- processed peptides in the barrel-like proteases upon isolation. A method of isolating barrel-like protease-processed peptides and a method of identifying barrel-like protease- processed peptides are also disclosed.

公开(公告)号：WO2022049567A2

公开(公告)日：2022-03-10

申请号：PCT/IB2021/061830

申请日：2021-12-16

申请人： AL-SEHEMI, Abdullah G. ,  CHINNAM, Sampath ,  PANNIPARA, Mehboobali ,  YALLUR, Basappa C. ,  CHIGURUPATI, Sridevi ,  GOWDA B.H., Jaswanth ,  PAUL, Karthika ,  SHIVANNA, Chandan Ravandur ,  VARDHARAJULA, Venkata Ramaiah

发明人： AL-SEHEMI, Abdullah G. ,  CHINNAM, Sampath ,  PANNIPARA, Mehboobali ,  YALLUR, Basappa C. ,  CHIGURUPATI, Sridevi ,  GOWDA B.H., Jaswanth ,  PAUL, Karthika ,  SHIVANNA, Chandan Ravandur ,  VARDHARAJULA, Venkata Ramaiah

IPC分类号： A61K31/54 ,  C07C303/40 ,  A61K31/00 ,  G01N33/502

摘要： A cluster of pneumonia cases and COVID-19 pandemic that started in Wuhan, China, was caused by novel beta coronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). Viral maturation requires the activity of the main viral protease (Mpro) and thereby, inhibition stops the advancement of the disease. The current invention delivers a potential anti-viral drug candidates docked against COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloquine and Umifenovir docked with COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E.Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of -14.00 kcal/mol.

公开(公告)号：WO2022031859A2

公开(公告)日：2022-02-10

申请号：PCT/US2021/044560

申请日：2021-08-04

申请人： CORNELL UNIVERSITY

发明人： BLENIS, John ,  DA SILVA GOMES, Ana Patricia

IPC分类号： G01N30/72 ,  G01N33/00 ,  G01N33/82 ,  G01N33/502

摘要： As described herein, increased levels of methylmalonic acid (MMA) or related metabolites are correlated with cancer. Methods and compositions are described herein for detecting and treating subjects with elevated levels of methylmalonic acid (MMA) or related metabolite compared to a control or standard level of methylmalonic acid (MMA) or related metabolite.

公开(公告)号：WO2021207282A2

公开(公告)日：2021-10-14

申请号：PCT/US2021/026059

申请日：2021-04-06

申请人： COMBANGIO, INC.

发明人： ALFORD, Spencer

IPC分类号： A61K35/28 ,  C12N5/0775 ,  C07K14/475 ,  A61K45/06 ,  A61K9/0048 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/19 ,  A61P27/02 ,  C12N2502/1352 ,  C12N2509/00 ,  C12N5/0621 ,  C12N5/0662 ,  G01N33/502 ,  G01N33/5058

摘要： The present application provides methods and processes for making and using a lyophilized mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the reconstituted lyophilized mesenchymal stem cell secretome described herein.